Page 11234..1020..»

Archive for the ‘Genetic Testing’ Category

What is Genetic Cancer Testing and How Do Patients Get Tested? –

At the molecular level all cancers are genetic, they start as your normal breast cell or ovaries and overtime pick up small genetic changes. When talking about inherited testing or hereditary testing only a small portion of cancer can be passed down in a family. We roughly quote 5-10% can be due to hereditary reasons or something we might find in an inherited genetic test, explained Dr. Tong at the CURE Educated Patient Womens Cancer Summit.

Genetic testing is a critical part of understanding these cancers, as well as how to treat, and Ill be discussing today about how we think about how genetics fits in cancer development, how genetic testing plays a role and how genetic counseling can help induvial and families come to decisions around genetics, says Dr. Tong.

Some exceptions include, up to 20% of negative breast cancers that can be hereditary and up to 25% of ovarian cancers can be hereditary, which is why genetic testing is recommended for all ovarian cancers.

When talking about hereditary cancer Dr. Tong says clinicians and genetic counselors are thinking about if that person has a higher chance of developing cancer, because nobody is at a 0% of developing cancer. Genetic testing will look at to see if they can identify what is elevating the persons risk of developing cancer, and can you potentially explain why a person developed certain cancer.

Part of what we learn from genetic testing, is not only could it have been due to a hereditary cause, such as a mutation in a gene, but which gene mutation and how can we differentially take care of people depending on which gene mutation did cause that, says Dr. Tong.

Guidelines recommend that all women diagnosed with epithelial ovarian cancer and breast cancer should be offered genetic testing.

Beginning in 2015 technology has brought three different types of gene testing or as they call it, Multi-Gene Panel Testing. Then there is a decision about how much genetic testing to do. For genes that they know are associated with inherited risk, those are high and moderate risk genes, they have actionable guidelines for treatment, risk reduction or prevention.

As technology develops you think about if the low-risk genes should also be looked at, the most likely have no impact on your health, such as a recessively inherited cancer risk, the information from these genes may be relevant to your family members or future generations. Some panel offers looking at newly described genes, they have limited evidence that they may impact inherited cancer risk, and they dont have actionable guidelines yet but could in the future.

We think that pretest counseling with a genetic counselor can help an induvial better understand how genetics impacts or plays a role in their cancer diagnosis or in their family history. Genetic counselors will take a look at family history and go many generations to look at distant relatives to see if there is a pattern to the cancers of that family that can be inherited, or does it look more like sporadic risks, then that counselor can discuss what the testing options are, how much testing to have or if its even right for you or not, says Dr. Tong about genetic testing counseling.

Types of results include a negative, the most important to be working with a genetic counselor, meaning there was no change found in the gene, it is considered a normal result and cancer treatment, screening and prevention decisions can be based on personal and family history of cancer. The next is a variant or uncertain significance, also considered a normal result, a change was found but is most likely due to normal human variation. The last result is positive result, where they find a change or genetic mutation that is associated with cancer, cancer treatment, screening and prevention decisions will be based on the risks specific to the change found.

Some may fear that they may be discriminated against due to their genetic testing results. There are laws in place that will protect you and your family members from employment or health insurance discrimination such as the Genetic Information Non-Discrimination Act of 2008, or GINA. In addition, there is the Americans with Disabilities Act, ADA, and the Health Information Portability and Accountability Act, HIPPA. However, there are limitations, how these laws dont protect against other types of discrimination such as life insurance, disability or long-term care, which would be discussed in your genetic counseling session.

Genetic testing can help thinking about what the path forward is for you and your family when we do learn the results, Dr. Tong concludes. He says going to a genetic counselor can help medically keep you healthy and also emotionally, connecting you with different resources and support organizations.

See more here:
What is Genetic Cancer Testing and How Do Patients Get Tested? -

Preimplantation Genetic Testing Market – Global Growth, Trends, and Forecast to 2025: Major Players are The Cooper Companies, Illumina, Thermo Fisher…

DUBLIN--(BUSINESS WIRE)--The "Preimplantation Genetic Testing Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to's offering.

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.

The major factor attributing to the growth of the market is a rising awareness among parents regarding advancements in diagnostics with a huge volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome, and common pediatric respiratory disorders such as pneumonia, and asthma are observed in recent years.

Key Market Trends

HLA Typing by Application Segment is Expected to Hold the Major Market Share in the Preimplantation Genetic Testing Market

The HLA typing by application segment is expected to account for the largest held the largest of the pre-implantation genetic testing market. Dominance can be owing to a rising volume of patients with damaged bone marrow or defective immune system. This results in an increased volume of hematopoietic stem cell transplantations (HSCT), necessitating the tests. Also, their increased application in evaluating interconnected matched donors and unrelated donors for safer HSCT is expected to drive the growth of the segment.

On the other hand, inherited genetic disease testing is anticipated to witness the highest CAGR during the forecast period. The lucrative growth can be due to their ability to detect diseases in offspring and increased awareness among the public about the inheritance of these diseases by future generations. Furthermore, steep rising incidences of inherited genetic diseases, such as Marfan syndrome, cystic fibrosis, fragile X syndrome hemoglobin disorders, and others, are driving the growth of the segment.

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the pre-implantation genetic testing market. The dominance is owing to a growing volume of chromosome abnormality cases leading to various genetic disorders. Aneuploidy is the most common causing Down syndrome among newborn babies in the united states, which holds the major revenue share in the North American market. According to the World Health Organization report published in 2018, down syndrome continues to be the most common chromosomal disorder affecting 6,000 babies born in the United States each year.

This, in turn, resulted in high demand for earlier diagnosis to identify the genetic defects in embryos drive the market in the region. Launch of new products by key players and a rise in improvements in healthcare infrastructure in the United States generates more revenue. Rise in government initiatives to create awareness in public and growing preference among couples for these tests during IVF and other artificial insemination procedures further stimulate the growth of the preimplantation genetic testing market in the region.

Competitive Landscape

The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and the launch of new products. In October 2019, PerkinElmer launched PG-Seq Rapid Non-Invasive Pre-implantation Genetic Testing Kit for Aneuploidy (PGT-A). It is a non-invasive alternative to conventional IVF embryo biopsies, which is expected to impact the market positively. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome

4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices

4.3 Market Restraints

4.3.1 Small Size of Study Population and Ethical Concerns

4.3.2 Highly Expensive Testing Procedures

4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage

4.4 Porter's Five Forces Analysis


5.1 Test Type

5.1.1 Preimplantation Genetic Diagnosis (PGD)

5.1.2 Preimplantation Genetic Screening (PGS)

5.2 Product and Service

5.2.1 Instruments

5.2.2 Reagents and Consumables

5.2.3 Software and Services

5.3 Application

5.3.1 HLA Typing

5.3.2 IVF Prognosis

5.3.3 Aneuploidy Screening

5.3.4 Other Applications

5.4 End User

5.4.1 Hospitals and Diagnostic Labs

5.4.2 Maternity Centers and Fertility Clinics

5.4.3 Other End Users

5.5 Geography


6.1 Company Profiles

6.1.1 The Cooper Companies Inc.

6.1.2 Illumina Inc.

6.1.3 Thermo Fisher Scientific Inc.

6.1.4 Quest Diagnostics Inc.

6.1.5 PerkinElmer Inc.

6.1.6 Invitae Corp.

6.1.7 Natera Inc.

6.1.8 Igenomix Sl

6.1.9 Bioarray SL

6.1.10 Genea Ltd


For more information about this report visit

Go here to see the original:
Preimplantation Genetic Testing Market - Global Growth, Trends, and Forecast to 2025: Major Players are The Cooper Companies, Illumina, Thermo Fisher...

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. – UroToday

Germline testing (GT) is increasingly impacting prostate cancer (PCa) management and screening, with direct effects in urology, medical oncology, and radiation oncology. The majority of testing indications and recommendations center on men with metastatic disease, although guidelines now encompass newly diagnosed, early-stage PCa and entail assessment of personal history, pathologic features, and family history to determine eligibility for testing.

To describe current guidelines on GT for men with PCa and the impact on management. An additional objective was to review the literature on current uptake of GT across practice settings.

A nonsystematic review was performed of current guidelines on GT in PCa from professional societies and consensus conferences, detailing supporting evidence for these recommendations. This was supplemented by a literature review of uptake of GT and precision medicine in practice.

Multiple guidelines and consensus panels recommend GT for men with metastatic PCa. Guidelines endorse BRCA2 testing in metastatic PCa because of strong evidence for PCa risk, aggressiveness, and PARP inhibitor candidacy. Testing of additional DNA repair genes in metastatic disease is also endorsed across guidelines. Immunotherapy with pembrolizumab is an option in some guidelines for men with DNA mismatch repair deficiency. In localized disease, GT is recommended on the basis of histologic features and family history; criteria vary between guidelines. GT for localized disease informs hereditary cancer risk and will probably impact future PCa management. Practice gaps exist regarding utilization of GT.

Germline evaluation is increasingly important in the management of men with metastatic PCa and may also affect the prognosis for men with localized disease. The presence of germline mutations has important hereditary cancer implications for men and their families. Uptake of germline evaluation may be underutilized in some practice settings, so strategies for optimization are required.

Patients with prostate cancer should talk to their doctor about the pros and cons of genetic testing, with attention to family history and cancer features. Genetic testing can have important implications for treatment, cancer screening, and family cancer risk.

European urology oncology. 2020 Dec 31 [Epub ahead of print]

Stacy Loeb, Veda N Giri

Department of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY, USA., Cancer Risk Assessment and Clinical Cancer Genetics, Departments of Medical Oncology, Cancer Biology, and Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: .


Original post:
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. - UroToday

Based on genes, nearly everyone is likely to have an atypical response to at least one drug – Scope

Every drug, from morphine to ibuprofen, has a standard dose -- a sort of one-size-fits all recommendation. But a new study suggests that when it comes to drug doses, "one size fits all" rarely applies.

Stanford Medicine professor Russ Altman, MD, PhD, and a team of scientists found that almost everyone (99.5% of individuals) is likely to have an abnormal or "atypical" response to at least one therapeutic drug. This, at least, is the case for people in the United Kingdom, as the study's data came from the UK Biobank, a project that collects, studies and shares data.

The research found that nearly a quarter of the study's participants had been prescribed a drug for which they were predicted to have an atypical response, based on their genetic makeup. On average, participants were predicted to have an atypical response to 10 drugs.

"Ultimately, the hope is that we can show how pervasive drug response variability is and encourage more doctors to rethink the standard prescription protocols that are largely used today and use genetic testing to predict and adjust forthis variability," said Altman, who is an expert in pharmacogenetics, a field that studies the intersection of drugs and genetics.

An "atypical" drug response encompasses a lot of things; but generally speaking, it means a certain drug might not affect one person the way it does another.

For instance, someone who has an atypical metabolic response might process that drug more efficiently, strengthening its initial effects but decreasing its efficacy over time. On the flip side, it could mean that that person is unable to metabolize the drug at all, leaving them without therapeutic aid, or even with dangerous side effects.

These differences in response to a drug are partially due to our genetics. Specific proteins -- workhorse molecules in the body -- break down drugs in order for the body to benefit from the therapeutic. Those proteins are regulated by a specific group of genes. Natural variation in those genes leads to differences in how an individual's body reacts to a given drug molecule.

Altman and his team, including graduate students and first authors of the study Greg McInnes and Adam Lavertu, analyzed data from nearly 500,000 participants.

For 230,000 participants in the study, the team had primary care data going back about 30 years. That includes which drugs had been prescribed, the dose, and all of the patient's different diagnoses. The researchers also had access to detailed genetic information about each patient. They paid special attention to genetic variations in a group of genes that are known to influence the human drug response.

By comparing an individual's genetics against the variations known to exist in the group of drug-response-associated genes, the researchers could predict how any given patient might respond to a drug.

"Pharmacogenetics as a field has been around for a long time, but it hasn't really been adopted into clinical use," McInnes told me. "It's been growing in the last few years as more people realize the impact that it could have on personalized health. For a long time, it's been this overlooked aspect of genetics that I think is actually one of the most clinically actionable advances that has come out of human genetics."

What's more, he said, the wide variability in the human drug response applies to common therapeutics most everyone has encountered or is familiar with -- ibuprofen, codeine, statins and beta blockers among others.

Moving forward, Lavertu says that the goal is to expand drug-gene variant interaction analyses into more diverse populations. The data from the UK Biobank provided critical insight, but it was largely only representative of a British population, where the majority shares European ancestry. A next step for the researchers is to investigate the same genes in the Million Veteran Program, a government research program with a more diverse study population, that is examining how genes, lifestyle and military exposures affect health and illness.

"Our hope is that doing more of these studies will help us find new relationships between genetic variants and drug response, so that pharmacogenetics can benefit more people," Lavertu said.

Photo byMicha Parzuchowski

Go here to see the original:
Based on genes, nearly everyone is likely to have an atypical response to at least one drug - Scope

Color hits $1.5B valuation, plans to build on testing infrastructure – MedCity News

Color, which started as a genetic testing service, quickly found a second use for its technology: facilitating Covid-19 testing.

The Burlingame, Calif.-based is working with more than 100 companies and governments to facilitate their testing programs, including Salesforce, United Airlines and the state of California, where it is working with PerkinElmer to process up to 150,000 Covid-19 tests daily.

Now, with $167 million in new funding, the company plans to continue to build out infrastructure for testing and other preventive services.

We realized one of the biggest challenges was how to get healthcare services to people, CEO Othman Laraki said in a phone interview. The Covid-19 crisis brought that focus with a lot of clarity.

Color was founded in 2015, and has since struck several high-profile partnerships. Last year, Alphabets Verily brought in the startup to provide genomic services for participants in its Project Baseline health study. It was also tapped by the NIHs All of Us Research Program to serve as the initiatives nationwide genetic counseling service.

In May, the company received an emergency use authorization to use loop-mediated isothermal amplification (LAMP) technology for Covid-19 testing, which uses a consistent temperature to amplify viral genome segments, instead of the multiple heating and cooling cycles with PCR testing. Two months later, it got the green light to use this technology for unmonitored testing, meaning patients can swab themselves.

Those experiences made Color realize that its biggest value was in this infrastructure that it had created, Laraki said.

People get excited about the science, he said. Really, most of public health is logistics. How do you make basic things available to people where they live and where they work?

With many states still grappling with how they will roll out Covid-19 vaccines to the public, Color also seeks to support that process. So far, the U.S. has grappled with shortages, wasted doses and challenges in determining how to best distribute a vaccine.

Weve had major health needs on the population side for a very long time. Its been death by a thousand cuts. Whats happening here is we are creating an access model for basic services at key social aggregation points: schools, employers, community settings, Laraki said. This is creating a national resource for access and distribution of these services that will outlast the current pandemic.

General Catalyst and T. Rowe Price Associates led the series D funding round, which values Color at $1.5 billion.

The opportunity to design the future of public health through technology cannot be overstated, General Catalyst Managing DirectorHemant Taneja said in a news release. Color understands that often, challenges in healthcare arent scientific or medical in nature, but rather due to access barriers. The hyper-scaling of access is perhaps the most impactful function of digital technology and the fact that Color approaches healthcare from this vantage point makes it among the most important companies in the industry.

Photo credit: aurielaki, Getty Images

See the original post here:
Color hits $1.5B valuation, plans to build on testing infrastructure - MedCity News

Preimplantation Genetic Testing Market Segments, Regional and Global Trends, Forecast and Competitive Landscape and Key Players -Inc. (US),…

Preimplantation Genetic Testing Market Overview: Introduction

Decisive Markets Insights publishes report on Global Market. According to business analysts, the market is anticipated to increase its value and volume over the forecast period 2020 2025 at a compound annual growth rate of x% over the next five years. The industry has witnessed business worth USD xx billion in 2019 and it is set to be at an estimated value of approximately USD xx billion by 2015. The growing trend is due to the market consolidation and widening consumer base and relaxation in the international tariff laws. Dominant players in the market are vying for a bigger share in the pie.

To know more about the report, visit @

Brief Summary of the Preimplantation Genetic Testing Market Report

The report covers extensive areas of economic fundamentals to explore the market dynamics. Both macro and micro level aspects have been included to explain the market trends and analyze and forecasts the investment opportunities. All the driving factors have been calculated to deeply delve into the subject of demand and supply chain in the market. To explain the minute structures and complexities of market trends data triangulation research method has been applied through. The challenges and the investment opportunities have also been covered. Other significant factors such as government agencies, socio-political structures, environmental conditions, and cultural norms of the geographies have been enumerated in detail. The report examines market trends on the basis on application areas, product types and key geographies highlighting the market trends.

Preimplantation Genetic Testing Breakdown Data by TypeGenetic Diagnosis/Genetic Screening

Preimplantation Genetic Testing Breakdown Data by ApplicationAneuploidy, Translocations

Preimplantation Genetic Testing Breakdown Data by CompaniesIllumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China)

Inquire before Purchasing the report, visit @

Segmentation and Scope of the MarketMarket segments of the global market have been provided below to understand the bi-furcation of the market. The market segments help the reader to understand the market from all the aspects.

Market Segmentation: Product, Application and Key Geographies

On the basis of product types and application areas, by geographies the market is segmented as North America, Europe, Asia Pacific and the Rest of the World (Row).

These geographical regions are further sub-divided into:

Reasons to Buy a Full Report

To Inquire about the Discount available with the report, visit @

**Note: Year End DiscountIf you purchase the report this year: Flat 15% instant discount 20% discount on 2nd report 1 Year consultation and 10 % free customizationKindly contact us and our expert will get back to you within 30 minutes:Decisive Markets InsightsSunil KumarSales HeadEmail sales@decisivemarketsinsights.comUS +18317045538UK +44125663604

See the original post:
Preimplantation Genetic Testing Market Segments, Regional and Global Trends, Forecast and Competitive Landscape and Key Players -Inc. (US),...

Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 – – Yahoo Finance

The "Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic Impact with Executive and Consultant Guides 2021 to 2025" report has been added to's offering.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry.

The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry. The report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Companies Mentioned

10x Genomics, Inc

23andME Inc

Abbott Diagnostics

AccuraGen Inc

Adaptive Biotechnologies

Admera Health, LLC

Agena Bioscience, Inc


Akonni Biosystems LLC

Anchor Dx

ArcherDx, Inc

ARUP Laboratories


Baylor Miraca Genetics Laboratories

Beckman Coulter, Inc

Becton, Dickinson and Company

BGI Genomics Co. Ltd

Bio-Rad Laboratories, Inc


Bioarray Genetics

Biocept, Inc

Biodesix Inc



Biolidics Ltd

bioMerieux Diagnostics

Bioneer Corporation

Cancer Genetics

Caris Molecular Diagnostics

CellMax Life


Chronix Biomedical


Clinical Genomics

And Many More Companies!

1. Introduction and Market Definition

1.1 Genetic Testing Definition in This Report

1.2 The Genomics Revolution

1.3 Market Definition

1.3.1 Revenue Market Size

1.3.1 Newborn Screening

1.3.2 Non Invasise Pregnancy Testing

1.3.3 Predictive

1.3.4 Oncology

Story continues

1.3.5 Direct to Consumer

1.3.6 Other Application

1.3.7 PCR

1.3.4 NGS

1.3.5 Cytogenetic

1.3.6 Other Technology

1.4 U.S. Medical Market and laboratory Testing - Perspective

1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

2.1 Market Participants Play Different Roles

2.1.1 Supplier/pharmaceutical

2.1.2 Independent lab specialized/esoteric

2.1.3 Independent lab national/regional

2.1.4 Independent lab analytical

2.1.5 Public National/regional lab

2.1.6 Hospital lab

2.1.7 Physician lab

2.1.8 DTC Lab

2.1.9 Independent Genetic Testing Lab

2.1.10 Audit Body

2.2 Genetic Tests -Types, Examples and Discussion

2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market

2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity

2.2.3 Newborn Screening

2.2.2 Diagnostic Testing

2.2.3 Carrier Testing

2.2.6 Predictive and Presymptomatic Testing

2.2.7 Pharmacogenomics

2.2.8 Forensic Testing

2.2.9 Parental Testing

2.2.10 Ancestral Testing

2.3 Industry Structure

2.3.1 Hospital's Testing Share

2.3.2 Economies of Scale Hospital vs. Central Lab

2.3.3 Physician Office Lab's

2.3.4 Physician's and POCT

2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Genetic Discoveries Creating New Diagnostic Markets

3.1.2 Aging Population a Boon for Diagnostics

3.1.3 Pharmacogenomics Drives Further Growth

3.1.4 Oncology and Liquid Biopsy Enter New Era

3.1.5 Fertility Practice Growth drives market

3.1.6 Direct to Consumer begins to break out

3.2 Factors Limiting Growth

3.2.1 Increased Competition Lowers Price

3.2.2 Lower Costs

Read more from the original source:
Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 - - Yahoo Finance

Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer – DocWire News

This article was originally published here

Clin Gastroenterol Hepatol. 2020 Dec 24:S1542-3565(20)31721-3. doi: 10.1016/j.cgh.2020.12.025. Online ahead of print.


BACKGROUND AND AIMS: Up to 20% of younger patients (age <50 years) diagnosed with colorectal cancer (CRC) have germline mutations in cancer susceptibility genes. Germline genetic testing may guide clinical management and facilitate earlier intervention in affected relatives. Few studies have characterized differences in genetic testing by race/ethnicity.

METHODS: We identified young adults (age 18-49 years) diagnosed with CRC between 2009 and 2017 in two health systems in Dallas, TX. We evaluated referral to genetic counseling, attendance at genetic counseling appointments, and receipt of germline genetic testing by race/ethnicity.

RESULTS: Of 385 patients with young-onset CRC (median age at diagnosis 44.4 years), 176 (45.7%) were Hispanic, 98 (25.4%) non-Hispanic Black, and 111 (28.8%) non-Hispanic White. Most patients (76.9%) received immunohistochemistry (IHC) for mismatch repair proteins, and there was no difference in receipt of IHC by race/ethnicity. However, a lower proportion of Black patients were referred to genetic counseling (50.0% vs. White patients 54.1% vs. Hispanic patients 65.9%, p=0.02) and attended genetic counseling appointments (61.2% vs. 81.7% White patients vs. 86.2% Hispanic patients, p<0.01). Of 141 patients receiving genetic testing, 38 (27.0%) had a pathogenic or likely pathogenic variant in a cancer susceptibility gene. An additional 33 patients (23.4%) had variants of uncertain significance, of which 84.8% occurred in racial/ethnic minorities.

CONCLUSION: In a diverse population of patients diagnosed with young-onset CRC, we observed racial/ethnic differences in referral to and receipt of germline genetic testing. Our findings underscore the importance of universal genetic testing to address racial/ethnic disparities in young-onset CRC.

PMID:33359728 | DOI:10.1016/j.cgh.2020.12.025

Read more here:
Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer - DocWire News

The Top 5 Most-Read Precision Oncology Articles of 2020 – Managed Markets Network

In August 2020, the FDA approved the first diagnostic test that combines next-generation sequencing and liquid biopsy. The test is intended to help guide treatment decisions for patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in metastatic nonsmall cell lung cancer (NSCLC), which is particularly deadly. The FDA called it a new era for mutation testing. The approval was granted to Guardant360CDx to provide information on multiple solid tumor biomarkers and to help identify EGFR mutations in patients who will benefit from treatment with osimertinib (Tagrisso), which is approved for a form of metastatic NSCLC.

Read the full article here.

4. Dr Andre Goy Discusses What Weve Learned About CAR T Therapies and Cytokine Responses

In a video interview, Andre Goy, MD,chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ,discussed what has been learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

Watch the interview here.

3. OneOncology, Foundation Medicine Create Partnership to Deliver Targeted Care

Also in August 2020, OneOncology, a network of nearly 170 community oncology care sites, and cancer genomic profiling firm Foundation Medicine announced a partnership to give patients and physicians access to genomic profiling tools as well as expanded research opportunities. In addition, OneOncology will help Foundation Medicine to create new assays for community oncology practices.

Read the full article here.

2. Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives

A study published in JAMA Oncology described how universalmultigene panel testingwas linked with increased detection of actionable, heritable variants beyond what one would expect to find using targeted genetic testing based on current cancer guidelines. The multicenter cohort study found that 1 in 8 patients had a pathogenic germline variant, half of which would not have been found if using guidelines alone. In addition, for the nearly 30% of patients with a high-penetrance variant, the findings led to a change in treatment.

Read the full article here.

1. How DNA Medicines Could Transform Treatment of Glioblastoma Multiforme

In an article appearing in the August 2020 edition of Evidence-Based Oncology, Jeffrey Skolnick, MD, the vice president of clinical development at biotech firm Inovio, discusses the companys proprietary technology that uses a computer algorithm to build DNA medicines that can target almost any antigen that can be presented to the human immune system through the major histocompatibility class I system. DNA medicines are built in the form of circular strands of synthetic DNA called plasmids, which can neither propagate nor integrate into the human genome. He also discusses their use in a potential application for glioblastoma, which is incurable.

Read the full article here.

Visit link:
The Top 5 Most-Read Precision Oncology Articles of 2020 - Managed Markets Network

Stock Markets Sink, but These 2020 Stock Winners Look Good for the New Year – The Motley Fool

New Year's celebrations are likely to look a lot different this year than most, as many people heed warnings to steer clear of mass gatherings during the global COVID-19 pandemic. Wall Street also seems to have had some cold water thrown on what was otherwise an extremely strong year for the stock market, as major market benchmarks are down at midday on New Year's Eve. As of noon EST, the Dow Jones Industrial Average (DJINDICES:^DJI) was down 39 points to 30,370. The S&P 500 (SNPINDEX:^GSPC) lost 3 points to 3,729, and the Nasdaq Composite (NASDAQINDEX:^IXIC) eased lower by 36 points to 12,834.

Yet even with the markets losing ground, several of the year's best-performing individual stocks kept up their momentum. Shares of Fulgent Genetics (NASDAQ:FLGT) and Celsius Holdings (NASDAQ:CELH) have already soared in 2020, but investors were willing to put more money to work and send their share prices still higher on the final day of the year.

FLGT data by YCharts.

Shares of Fulgent Genetics were up more than 10% on Thursday at midday. The genetic testing and diagnostics company has gotten a lot of business from the pandemic, and Fulgent continues to pull in customers and demonstrate its value to shareholders.

Fulgent found itself in the right place at the right time in 2020, with its quick work in coming up with coronavirus tests leading to an at-home sample-collection kit that received approval from the U.S. Food and Drug Administration in June. The company's third-quarter revenue skyrocketed as a result, topping the $100 million mark after doing just $10 million in business in the same period of 2019.

Image source: Getty Images.

Some fear that now that coronavirus vaccines are available, Fulgent will see its COVID-19 testing fall off a cliff. However, with the rollout of vaccines going at a slower pace than many had hoped for, there'll still be plenty of need for coronavirus tests well into 2021. And more importantly, with Fulgent having demonstrated its ability to respond quickly in a crisis, the company has made valuable contacts in the healthcare and insurance industries that should serve to produce further growth opportunities in the years to come.

Fulgent has more than quadrupled investors' money in 2020. It might not jump another 300% or more in 2021, but the genetic-testing specialist has plenty of chances to keep its stock moving higher.

Shares of Celsius Holdings fared even better, rising more than 13% at midday. That's consistent with what's been an amazing year for the energy-drink specialist, with its stock jumping to more than 10 times where it started the year.

The latest surge for Celsius came as a result of a move from index managers at S&P Dow Jones Indices. Celsius will join the S&P SmallCap 600 Index effective as of Jan. 7. The move stems from an acquisition involving a company in the S&P 500, which created a cascade effect that eventually created a vacancy in the small-cap index.

Celsius joined a highly competitive arena with its energy drinks, but the company's focus on fitness and performance resonated well with consumers. Revenue has jumped more than fivefold in less than four years, and Celsius turned profitable in 2019 and has managed to maintain its bottom-line strength, even in the difficult current environment. That's a big part of what's attracting attention for the company, and it holds the key to Celsius' future success.

Investors must not get used to seeing stocks climb 300%, 500%, or even 1,000% in a year. However, when it happens, it often signals strength that will continue. Investors should expect to see more good things from Celsius and Fulgent in 2021.

Continued here:
Stock Markets Sink, but These 2020 Stock Winners Look Good for the New Year - The Motley Fool

How to Make 2021 Your Healthiest Year Yet – Sarasota

Take a deep breath 2020 is over and a new year has just begun. After months of fear caused by the Covid-19 pandemic, its time to turn the page, look ahead and start taking care of yourself. And weve got all the info you need to do just that. From enrolling in a Zoom fitness class to consulting with a genetic counselor, weve compiled dozens of ways for you to make 2021 your healthiest, and best, year ever.

For local fitness instructors, offering workout routines through Zoom or other video platforms has been a godsend during the pandemic. The technology allows them to reach clients who dont feel comfortable coming to the gym, and it also makes it harder to wiggle out of a workout. Running late and dont have time to drive to the gym? That excuse wont cut it anymore.

Many local fitness studios, like Chica Boom Fitness and Anytime Fitness, have begun offering workouts on Zoom or Facebook. Local trainers will guide you through daily workouts that mix weight training for specific muscle groups and both high- and low-impact cardio workouts.

Some even offer creative substitutions if you lack the necessary workout gear at home. Dont have kettlebells? Grab two full gallon water jugs instead. Dani Williams, who owns Nxt Generation, a fitness company that offers classes at the Sarasota studio Definition Fit, says Zoom classes offer flexibility for both the trainer and the client.

Williams works primarily with children and young adults, many of whom have special needs. Remote classes make it easier for them to show up each week, wherever they are. Travel is a big thing that prevents people from keeping a routine, says Williams. Its a really nice feature to have.

Even once the pandemic passes, Williams thinks remote fitness lessons will only grow in popularity. Local athletes can train with coaches all over the world, and local trainers can reach customers anywhere. Ive found great success with it, Williams says. Cooper Levey-Baker

Sarasota counselor Audrey Oxenhorn says committing to regular appointments with a therapist can make a huge difference in ones mental health, but the real work happens in between those meetings. An hour a week is never enough, says Oxenhorn.

To help people stay on track, Oxenhorn often recommends The Tapping Solution, an app that guides people as they tap on specific acupressure points on their body. The tapping, combined with calming sounds and words, is intended to reduce stress and anxiety. The app relies on a method that has been around for decades, but it has made it more accessible for millions of people. The technique and the app dont work for all of Oxenhorns clients. But when it does, its spectacular, she says.

The Tapping Solution is only one of dozens of apps that offer guided meditations and other programs that target anxiety, stress, fear, anger and other negative emotions. Headspace, for example, claims it has more than 65 million users in 190 countries, and has partnered with major companies like Nike and Starbucks. Other popular options include Moodfit, Sanvello and Happify.

According to Oxenhorn, apps make it easier for people struggling with mental health to take that first difficult step toward getting help and they give them tools to improve their mental health outside of a therapists office. I especially want to teach people to do the work themselves, so they can be happier and more fulfilled in what they do, Oxenhorn says. Cooper Levey-Baker

More and more people who have trouble falling, and staying, asleep are turning to melatonin, but does it work? According to Dr. Glenn Adams, a sleep medicine specialist and the medical director for Sarasota Memorials Sleep Disorder Center, the answer is: sometimes, for some people.

Melatonin is a naturally occurring substance in humans. Levels typically rise when it gets dark, cueing our bodies that its time for sleep. But as we grow older, our bodies produce less. At a young age, we have more than enough melatonin, says Adams. When youre 20 or 30, any benefits of taking it will be placebo.

Adams says there are no rigorous studies about melatonins benefits, but some do show that it may help you fall asleep 15 minutes sooner. That might help if it normally takes you 30 minutes to fall asleep, but if it usually takes you two hours, the benefit may be minimal.

With over-the-counter melatonin, the customer doesnt know exactly how many milligrams of melatonin he or she is getting, so Adams recommends sticking with the same brand for a consistent dosage. Side effects can be occasional nightmares, or even feeling a bit hungover when you wake up in the morning. If you do try melatonin, Adams says that once or twice is not enough to see if its working. Give it longer. Kay Kipling

Beet juice is the latest superfood to gain widespread attention, and whats not to like? Its low in caloriesone cup of beet juice has just 100 caloriesand its full of nitrates that improve your blood flow and help lower your blood pressure. According to one national study, people who drank beet juice for six days had better stamina to exercise more intensely.

Thats why its such a great pre-workout juice, says Lynn Morris, the owner of SaraFresh, which recently opened a retail store in the Rosemary District. SaraFresh specializes in cold-pressed juices, which have more nutritional value than pasteurized juices you find in the grocery store.

Morris says her new crowd favorite is something she calls Beetiful, a blend of beet, apple, lime and ginger, and she also offers 2.5-ounce beet shots. Shes also adding beet juice to her La Vie En Rose vegan ice cream to give it its signature rose color. By the way, dont panic if, after drinking beet juice, your urine turns reddish. Thats perfectly normal. Ilene Denton

Telemedicine has been around for years, but the Covid-19 pandemic has caused a massive rise in the number of doctors who offer consultations over the phone or through apps. But physicians cant take your vitals over the phone, so, more and more, they are relying on clients equipping themselves with tools to monitor their own data.

QardioArm, for example, is a home blood pressure monitor that delivers results to your phone and can share your numbers directly with your physician. Withings, meanwhile, is a smart scale that can also measure your bone, muscle and fat mass, and even adjusts for different gravity levels where you live to accurately determine your weight. Pulse oximeters that measure the oxygen level in your blood have also been flying off the shelves since the arrival of the coronavirus, as have affordable no-touch thermometers that read your temperature by scanning your forehead. Cooper Levey-Baker

At Scorch Fitnesswhich specializes in HIIT, or high-intensity interval traininga typical in-person session might last 45 to 50 minutes. But even workouts as short as 10 minutes can yield results, says Scorch owner Liz Lowe. Such brief sessions are known as micro HIIT workouts and are done at your own home. No instructor is needed. Just pick a combination of workouts (squats, a forearm plank and mountain climbers, for example) and get to work.

Micro HIIT workouts have become an increasingly popular way for people to squeeze in a good sweat between Zoom meetings, picking up the kids and running errands. I think micro HIIT is great for people who are strapped for time or if youre just getting into training, Lowe says.HIIT works by combining aerobic and anaerobic exercises that get your heart rate soaring, then alternating those with shorter periods of less strenuous activity. The Scorch program was adapted from workouts Lowe created for professional athletes, and it is designed to help you simultaneously burn body fat, add muscle and increase your resting metabolism. Micro HIIT exercises do the same thing, just in briefer windows of time.

If youre interested in trying them, Lowe recommends starting by finding exercises that just use your body weight. If you reach a point where you want to begin using weights, she recommends consulting with a trainer to make sure your form is correct. The last thing you want to do is get injured, Lowe says. Cooper Levey-Baker

When people talk about gut health, theyre not just talking about your stomach. The term gut refers to your whole gastrointestinal tract, which is covered in trillions of microscopic living organisms that help regulate a host of bodily systems, including immunity and weight.

But maintaining a healthy gut isnt always easy. Tens of millions of Americans suffer from digestive conditions like irritable bowel syndrome, nausea, bloating and constipation.

Gastroenterologist Nihar Shah of First Physicians Group says you can keep your gut healthy by eating foods rich in pre- and probiotics, such as apples, garlic, sweet potatoes, oats, chia seeds, onions, berries, kimchi, pickles, sauerkraut and yogurt. Shah also recommends colonoscopies once every 10 years once you reach 50 to screen for colon cancer. A healthy gut can play a role in preventing that, too.

Theres a direct link between colon cancer and consuming red meat and processed meat, so I recommend decreasing both of those things, as well as processed and genetically modified foods, says Shah. Also important: maintaining a healthy weight, getting a good nights sleep and exercising regularly.

And if youre taking any antibiotics, make sure to supplement your diet with those probiotic-rich foods, which can wipe out the good bacteria thats so important to a healthy gut. Megan McDonald

Over the last 20 years, genetic testing has emerged as a valuable tool for analyzing and even mitigating all kinds of medical conditionsincluding cancer. But testing is more road map than crystal ball. Nothing is definite. Everything is just about risk, says Nicole Wood, the oncology genetic counselor for Sarasota Memorials Genetic Testing for Hereditary Cancer program.

The genetic testing process begins with an extensive conversation with a genetic counselor, who will ask about your own medical history as well as your familys. If you opt for a genetic test, it only requires a blood draw.

[Your genetic makeup] is not new. Its something youve always carried since birth, says Wood. We use it to modify what were doing with your cancer care, screening, medical management, etc. Whatever train youre on that might lead to cancer, we can redirect it.

Still, genetic testing isnt for everyone, and theres good reason not to rush out and get tested willy-nilly. Once you know this information, you cant un-know it, says Wood.

Genetic testing technology continues to evolve at warp speed. Wood estimates that the number of genes that can be tested for cancer risk will double in two years. Wood even sees the probability of genetic manipulation in the future. Can we change these genes? she asks. Maybe." Hannah Wallace

Fitness experts say switching up your workouts is a good thing. You wont risk repetitive injuries and youll stimulate your brain at the same time. Foil boarding, a combination of windsurfing and wakeboarding, fits the bill.

Foil boarding starts with the hydrofoil, a wing-like structure that extends below the board into the water and lifts the board up so the rider looks like she (or he) is soaring a couple of feet above the water. This propeller allows riders to achieve speeds six knots faster than recorded gusts on a windy day. Add a parachute, and riders can really fly. The sport has become popular along the Gulf Coast, where youll spot riders levitating and landing tricks.

If youre looking to give it a try, you can purchase a board from the Venice board-making company Phase Five. The company has three different boards to choose from: the Gizmo ($1,270), the Chip ($1,270) and the Gadget ($989), which range from 44 to 54 inches long. Beginners should start with a longer board and foot straps to assist with training. Experienced surfers can try out shorter boards to glide through the air and land tricks. Allison Forsyth

Go here to read the rest:
How to Make 2021 Your Healthiest Year Yet - Sarasota

These Were the 5 Top Genetics Stocks of 2020 – Motley Fool

Genetics is a high tech, research-intensive business. Between the complexity of the science and the demands of the clinical trials and regulatory approval process, it's also quite risky -- but the rewards can be immense.

Many genetics companies spent the year working on the projects that might become their first sources of revenue. The market reacted to their every peep, and there's a good chance that several of these stocks will have another bumper crop year in 2021.

Image source: Getty Images.

Selling coronavirus diagnostic tests is big business, as shown by the 990% rise of Co-Diagnostics (NASDAQ:CODX) this year. With quarterly revenue growth exceeding 52,559% year over year, it's easy to see why the market was so enthusiastic about the company. Moving forward, it will penetrate foreign markets like India, selling tens of millions of its molecular test kits in the process.

Furthermore, Co-Diagnostics is moving quickly to develop new genetic tests that can detect viral mutations for the laboratory research market, ensuring that it will stay relevant through next year and beyond. Investors should look forward to another great year in 2021, with the caveat that it'll be tough to grow nearly as quickly as it did this year now that the testing market is significantly more crowded with competitors.

Arcturus Therapeutics (NASDAQ:ARCT) surged nearly 300% in 2020 by advancing its mRNA-based coronavirus vaccine program, which should enter phase 2 of its clinical trials in the first quarter of 2021. Though its candidate isn't as closely watched as several of the other leading contenders, there's a lot riding on its success. Like many biotech companies, it doesn't have any products on the market or any recurring revenue to speak of. That might change next year if its vaccine is proven effective. But, the early signs don't look good. A recent clinical update showed that its candidate might not be as protective as the other mRNA vaccines that are already approved for sale.

Investors can take heart in the fact that with just over $307 million in cash, Arcturus has enough gas in the tank to explore a few options for boosting the vaccine's efficacy. Until then, they can sit pretty on the stock's growth this year. If you're interested in investing, the only thing to do at the moment is to watch for clinical trial updates to see how its core project is advancing.

Given how many hopes were riding on its coronavirus vaccine candidate, you shouldn't be surprised to see Moderna (NASDAQ:MRNA) on this list. With growth of around 467%, Moderna will likely turn a profit for the first time next year as its vaccines are sold at mass scale. But, its stock may not be able to keep up with the valuations that 2020 built with hype.

Whether its first earnings reports in the new year will herald a reckoning is anyone's guess. Nonetheless, in the long-term its older pipeline projects will start to come to fruition. Some of those have the potential to be hugely disruptive, like its personalized cancer vaccine collaboration with Merck. Others, like its cytomegalovirus vaccine, may not make a big splash. Investors should watch the company's pipeline updates carefully, not to mention its earnings reports. There's every indication that its vaccine will be a big moneymaker, potentially to the tune of $32 billion in 2021. So, the real question is: What management will choose to spend the windfall on?

CODX data by YCharts

Inovio Pharmaceuticals (NASDAQ:INO) grew by 173% this year thanks to its coronavirus vaccine program. Like Moderna, Inovio's pipeline also has a smattering of lesser-known vaccines in development, none of which garnered the market's attention very much. Until this year, that is. Once the U.S. government's vaccine accelerator program invested in Inovio, it quickly entered the spotlight.

There's reason to be excited about Inovio moving forward, too. In mid-December, it announced that the government had taken an interest in developing a DNA-encoded monoclonal antibody therapy for COVID-19 using the company's technology. Likewise, its vaccine administration device developed with public funding may be key to its future success. Still, its coronavirus programs need to be proven definitively in clinical trials next year if its stock is to grow any further, and doubts remain about the viability of its DNA-based vaccines.

Thanks to hot demand for its coronavirus diagnostic products, Fulgent Genetics (NASDAQ:FLGT) grew by 280% in 2020, and its management increased its full-year revenue guidance by $100 million in November. Its revenue expanded by more than 880% in the third quarter compared to 2019, and the company is firmly profitable. Plus, its $2.74 million in debt barely holds a candle to its trailing revenue in excess of $135 million. There's a lot for investors to like, to say the least.

There's more to the company than its coronavirus tests, however. It also offers genetic testing for a handful of hereditary cancers and other disorders. Further investment in expanding its market penetration with these products will help to keep the company's momentum next year and beyond. In the meantime, investors can look forward to the next quarterly earnings report, which almost certainly will have even more good news.

See original here:
These Were the 5 Top Genetics Stocks of 2020 - Motley Fool

Genetic Testing Services Market Research Report is Projected to Witness Considerable Growth by 2026 – Farming Sector

Genetic Testing Services Market Overview:

Research report on the Genetic Testing Services market by Market Growth Insight covers deep analysis on key factors that help business players to plan their future actions accordingly. The Genetic Testing Services market report discloses vital information like market share, market size, and growth rate for the forecast period 2020- 2026. The report on Genetic Testing Services market also comprises information on the stringent government regulations in key regions, such as import and export status, product price, FDA approvals, consumer buying behavior, Further the Genetic Testing Services market is categorized on the basis of product, end use industries, and region.

Global Genetic Testing Services market is anticipated to reach USD XX billion by the end of 2020 along with CAGR of XX % over the forecast period 2020 2026.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

Global Genetic Testing Services Market segments by Manufacturers:

Major Type of Genetic Testing Services Market Covered:

Application Segments Covered in Market

COVID-19 Analysis:

The disturbances caused by the novel Coronavirus is being witnessed by all the industries. Some of the major interruptions include cancellations of flights, disruptions in logistics, reduced demand and production, delayed supply of essential raw materials, rejected delivery of key components to the end use industries, increased panic among consumers, higher pressure on healthcare industry, and more. Several key regions are also experiencing prolonged lockdown due to speedy spread of the virus. Also businesses are witnessing many disturbances including delayed product launches, interruptions in innovations, and less working population in work areas. Nevertheless, researchers have mentioned about the strategies adopted by key vendors during pandemic and other planning and activities to alleviate the Genetic Testing Services market post-pandemic.

The Genetic Testing Services market discusses details on the leading product type. The Genetic Testing Services report also offers deep analysis on the potential product segment that is expected to lead in the forthcoming years. Also, information on other product segments is given in the Genetic Testing Services market report to help the competitors and customers get a clear picture of the market and details on the upcoming product, respectively.

The Genetic Testing Services market research report provides detailed information on the dominating end use industry that demand the product on a larger scale along with details on the potential end use industry that is anticipated to surpass the demand of the current prominent end use Genetic Testing Services industry.

Get Special Discount @

Regional Analysis of Genetic Testing Services Market Research Report:

The Genetic Testing Services market report is segmented as North America, Latin America, Asia Pacific, Europe, and Middle East and Africa. These regions are described well and elaborated with demographic insights and potential lucrative regions for the business owners to tap and expand their business geographically. This will also help the producers to understand the demands of consumers in a better way and manufacture goods accordingly.

In addition, competitive analysis is also precisely mentioned in the Genetic Testing Services report to help the new entrants plan effective establishment policies and approaches and gain prominent position among competitors. The commonly adopted growth strategies are also included in the Genetic Testing Services market report. Also, the existing players can plan effective approaches for future and gain leading ranking.

Some of the queries answered in the report comprise:

Make an Enquiry for purchasing this Report @

About Market Growth Insight

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas. The skilled and experienced professionals at Market Growth Insight are our strength and the position we have earned in the industry. This is what makes us to offer our clients to excel and enable competitive prices while retaining the best services. We are incorporated with a vision to provide the complete solution required for successful business execution. Our only motto is to resolve customer fulfillment completely. We provide the quality and customized research reports from the best publishers in the world.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:

Read more here:
Genetic Testing Services Market Research Report is Projected to Witness Considerable Growth by 2026 - Farming Sector

Predictive Genetic Testing and Consumer/Wellness Genomics Market Rear Excessive Growth During 2017 to 2025 – Farming Sector

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See more here:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Rear Excessive Growth During 2017 to 2025 - Farming Sector

Predictive Genetic Testing Market Size 2020, Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2025 -…

The market research report contains important details regarding the Predictive Genetic Testing market value based on market dynamics and various growth factors. It examines various key aspects of the market, including the latest technological innovations in the industry, current trends, and development opportunities. In this report, we analyze the Predictive Genetic Testing industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions at the same time, we classify different Predictive Genetic Testing based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Predictive Genetic Testing industry development trends and marketing channels are analyzed. In addition, this report introduces market competition situation among the vendors and company profile, and besides market price analysis and value chain features are covered in this report.

Get A Sample Copy of Research Report at:

The report represents the exact condition of the current market which includes Business Opportunity, Innovations, Upcoming-Trends, Growth-Analysis, Demand-Insight, Top-Manufacturers for the forecast year 2020 to 2025. Our board of exchange experts has immense enormous endeavors in doing this gathering activity so as to deliver important and dependable essential and optional information with respect to the Predictive Genetic Testing market.

Essential Key Players involved in Global Predictive Genetic Testing Market are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Browse the complete report Along with TOC @

The detailed information in this reports will help the companies to make informed Marketing strategies. Moreover, ultimate goal of Market research is to analyze how the Markets target group will obtain a product or service. Market research report is predominantly prepared following certain methodology and guidelines for collecting, organizing and analyzing data. It also delivers the business models, strategies, growth, innovations and every information about key manufacturers that will enable in making business estimates. In addition, every Market has a set of manufacturers, vendors and consumers that define the Market as well as their every moves and achievements becomes a subject of studying for Market analysts.

Global Predictive Genetic Testing Market: Understanding ScopeBearing in mind the need for reader convenience, seasoned researchers of our in-house teams have identified 2020 as the base year and pinned the years between 2020-25 as the overall growth span. This is likely to give a glimpse of both the past and current happenings that systematically influence forecast estimation. Additionally, the report also takes into account the CAGR estimation and percentage that is likely to remain optimistic through the forecast span.

Market SegmentationMarket by Types

by Types (Predispositional Testing and Presymptomatic Testing), by Demographics (<35, 35 ? 64 and 65+)

An Overview of Regional Developments: Global Predictive Genetic Testing Market The overall spectrum of the global Predictive Genetic Testing market is broadly diversified into North and South America, Europe, APAC, and MEA. The report gauges into vital details such as manufacturer performance and overall growth activities across potent growth hubs. A close review of the overall growth rate during both past and current timelines have been meticulously highlighted to encourage thoughtful business decisions in global Predictive Genetic Testing market A clear reference of the overall revenue generation, sales performance as well as growth rate synopsis have been thoroughly structured in this versatile research report on global Predictive Genetic Testing market. Further in the report, readers are presented with substantia, cues on vendor landscape, frontline players and their company profiles and performance analysis have all been optimally highlighted in this report to encourage adequate reader discretion.

Chief Reasons for Report Investment The report lends a highly time specific, forward-looking scenario of the global Predictive Genetic Testing market The report offers a highly systematic overview of DROT analysis, involving detailed explanation of key market drivers, constraints, risks, and growth opportunities. The report also includes a complete five-year forecast assessment that allow manufacturers well gauge into futuristic growth probabilities The report is a handy-ready-to-refer guide to emphasize workability and growth potential of each of the segments, allowing readers to comprehend the investment potential of each segment. The report is an indispensable guide to understand and carry out a pin-point analysis of the fast-changing competitive landscape to encourage well informed business decisions favoring sustainability and long-term revenue generation potential in global Predictive Genetic Testing market.

3-Pointer Evaluation of COVID-19 Impact The report renders a thoroughly evaluated market outlook of the world perspective and the overall economic overview Stark differences and alterations in demand and supply chains have been highlighted A crisp pre and post COVID-19 developments and beyond have also been tagged in this corporate report on global Predictive Genetic Testing market.

Considering the existing market scenario, our seasoned researchers and expert panelists have relied heavily on intense research practices to offer an extensive range of market predictions for an exhaustive clientele reference of dynamics, dominating global growth outlook in Predictive Genetic Testing market. The unprecedented outrage of COVID-19 pandemic has affected adversely several businesses across industries. We aim to offer highly reliable and relevant action plan to offset the implications for further growth spurt in global Predictive Genetic Testing market. Customization remains crucial decision maker that always keeps us most preferred market intelligence provider for a burgeoning clientele.

Make an enquiry of this report:

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

View post:
Predictive Genetic Testing Market Size 2020, Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2025 -...

Preimplantation Genetic Testing Market Size, Share, Growth Trends, Revenue, Top Companies, Regional Outlook, and Forecast, 2020-2027 – LionLowdown

New Jersey, United States,- The report, titled Preimplantation Genetic Testing Market Research Report is based on the extensive analysis of analysts and contains detailed information on the global market area. A detailed examination of the business landscape, as well as the essential parameters that shape the marketing matrix of the market, is included.

A thorough qualitative and quantitative study of the global market has been conducted in this report. The study takes into account various important aspects of the market by focusing on historical and forecast data. The report provides information on the SWOT analysis as well as Porters Five Forces Model and the PESTEL analysis.

The Preimplantation Genetic Testing Market research documentation provides details on drivers and restraints, regional growth opportunities, market size, as well as the spectrum of competition, prominent market candidates, and segment analysis.

The following Manufacturers are covered in this report:

The report aims to enumerate various data and updates related to the World Market while developing various growth opportunities that are believed to support the market growth at a significant rate during the forecast period. The report provides an insightful overview of the Preimplantation Genetic Testing market along with a well-summarized market definition and detailed industry scenario.

A comprehensive summary revolves around market dynamics. The segment encompasses insights into the drivers driving the growth of the Preimplantation Genetic Testing market, restrictive parameters, existing growth opportunities in the industry, and the numerous trends that define the global marketplace. The report also includes data on pricing models and a value chain analysis. The expected growth of the market during the analysis period based on the estimates and historical figures has also been factored into the study.

The Preimplantation Genetic Testing market report provides details of the expected CAGR recorded by the industry during the investigation period. Additionally, the report includes a number of technological advances and innovations that will boost the industrys prospects over the estimated period.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

1.Label-Free Detection Market, By Technology:

1.Label-Free Detection Market, By Products:

3.Label-Free Detection Market, By End User:

4.Label-Free Detection Market, By Application:

Geographic Segmentation

The report offers an exhaustive assessment of different region-wise and country-wise Preimplantation Genetic Testing markets such as the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa

What are the main takeaways from this report?

A comprehensive price analysis was carried out in relation to product area, range of applications and regional landscape A comprehensive round up of the key market players and leading companies operating in the Preimplantation Genetic Testing Market to understand the competitive perspective of the global marketplace Important information on the regulatory scenario that defines the market, as well as the inflow of investments from majority stakeholders in the world market An in-depth assessment of the various trends that are fueling overall market growth and their impact on global market projection and dynamics A descriptive guide that identifies the key aspects along with the many growth opportunities in the Preimplantation Genetic Testing market A detailed documentation of a wide variety of ongoing issues in the world market that will encourage important developments

Some Points from Table of Content

1. Study coverage2. Summary3. Preimplantation Genetic Testing Market Size by Manufacturer4. Production by region5. Consumption by region6.Preimplantation Genetic Testing Market Size by Type7. Preimplantation Genetic Testing Market size according to application8. Manufacturer profiles9. Production forecasts10. Consumption forecasts11. Analysis of customers upstream, industrial chain and downstream12. Opportunities and challenges, threats and influencing factors13. Main results14. Appendix

Verified Market Intelligence is a BI enabled database service with forecasted trends and accurate market insights on over 20,000+ tracked markets helping organizations globally with their market research needs. VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment and Key players for emerging and niche markets.

About Us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

View post:
Preimplantation Genetic Testing Market Size, Share, Growth Trends, Revenue, Top Companies, Regional Outlook, and Forecast, 2020-2027 - LionLowdown

San Diego County ends 2020 with largest single-day COVID-19 death total of the year – The San Diego Union-Tribune

A waning 2020 delivered a final kick on the way out Thursday with the county health department announcing 62 additional COVID-19 deaths, a new single-day record arriving on New Years Eve.

And there was an extra reason for concern. The county public health lab, working with local researchers, confirmed three more cases of the United Kingdom coronavirus strain Thursday, bringing the total to four, including the initial case involving a man in his 30s announced Wednesday.

Officials said none of the four are related and had no contact with each other before testing positive.

The three additional cases confirmed Thursday were all men. Case investigators have interviewed two of the three who reported no recent travel outside the country. Two of the three new cases were in their 40s and the third was in his 50s. The third case for whom travel information was not available had not yet been interviewed.

They live in La Mesa, Otay Mesa, Mission Beach and the Rancho Bernardo-Carmel Mountain area.

The county public health lab was still awaiting the results of genetic testing to confirm whether a close contact of Wednesdays first UK strain subject, who was said to have been experiencing symptoms of coronavirus infection, also has the UK strain.

Dr. Eric McDonald, medical director of the countys epidemiology department, said Thursday evening that the subject, a woman also in her 30s who is the spouse of Wednesdays UK case, has been admitted to a hospital after testing positive for coronavirus. Genetic testing being performed by Scripps Research will be necessary to confirm that the UK strain was involved, but that seems very likely at this point.

I would be shocked if it doesnt come back with whole-genome sequencing that confirms it, McDonald said.

He said the three additional UK cases confirmed through genetic testing Thursday were actually tested between Dec. 20 and Dec. 22. Helix, a local company that the county contracts with for testing, looked through its records after the first case appeared and discovered the results as having the telltale s drop signature that marked Wednesdays case.

Having cases from different parts of the county that did not know each other, he said, shows that this strain, which is thought to spread more easily than other variants, has been among us for some time.

This didnt just spread to that many different parts of the county among people who dont know each other in the past two weeks, McDonald said. The dispersal of these cases geographically tells you that it has probably been in the county for a longer period of time.

With 99 deaths announced in just the past two days, December is by far the deadliest month of the pandemic. According to county records, 488 deaths have been recorded in December, more than twice the previous monthly record of 197 tallied in July.

The most recent deaths announced Thursday range in age from 45 to 100 with three in their 40s. As is always the case, the deaths announced on any given day did not all occur the day before the announcement. It can take days or weeks for death certificates and causes of death to be finalized before they are reported to the public.

Taking the latest group into account, records show that a total of 28 deaths occurred on Dec. 22, tying Dec. 18 for the deadliest day of the pandemic.

McDonald said he reviews each and every death certificate before the county releases new numbers. Seeing so many in December, he said, has been particularly harrowing.

Every one of those is a person and has a family, McDonald said. What this means is that there are more and more San Diego families that are coming to grips with the fact that this is a real and deadly pandemic.

Deaths are what epidemiologists call a lagging indicator, generally occurring weeks or months after infections take hold. As such, a spike in deaths does not, in and of itself, say all that much about how a pathogen such as the novel coronavirus is spreading in a community. The number of new positive cases coming in daily provides a more immediate sense of the current pace of infection.

The final COVID-19 report of 2020 lists 3,083 new cases, once again jumping over the 3,000 mark after three straight days below that mark. The result could signal the arrival of a new wave of cases connected to Christmas celebrations, given that the average incubation period for the virus the amount of time spent in the body before symptoms generally begin to appear is about 6 days, according to the U.S. Centers for Disease Control and Prevention.

Pressure continues to mount on local hospitals with 1,580 total COVID-19 patients in beds across the county Wednesday. COVID-positive patients occupied 35 percent of the 4,504 total beds in use. Intensive care admissions held steady at 621 with 386 having a COVID-19 diagnosis and 235 without.

Read this article:
San Diego County ends 2020 with largest single-day COVID-19 death total of the year - The San Diego Union-Tribune

Direct Genetic Testing for Consumer Market is expected to show impressive growth rate between 2020 to 2026 – LionLowdown

The Direct Genetic Testing for Consumer Market report was conducted across a variety of businesses in various regions to produce a worthy report that represents the proficient analysis of the industry. The report provides a competitive study of leading market players, market growth, consumption (sales) volume, key drivers and limiting factors, future projections for the new-comer to plan their strategies for global Direct Genetic Testing for Consumer Market business. The report highlights key market expansions, industry and competitors challenges in gap analysis and new opportunities and key trends in the market. The report studies many aspects of the industry like the market size, market status, market trends and forecast from 2020 to 2026 time period.

Report Overview:

Report Ocean analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry. We will also include the impact of COVID-19 new strain found in UK.

Request Free Sample Report at

The global Direct Genetic Testing for Consumer Market research study is to define market sizes of various segments & countries by past years and to forecast the values by next 5 years. The report is assembled to comprise each qualitative and quantitative elements of the industry facts including market share, market size (value and volume 2015-19, and forecast to 2026) which admire each country concerned in the competitive examination. Further, the study additionally caters the in-depth statistics about the crucial elements which includes drivers & restraining factors that defines future growth outlook of the market.

Competitive Landscape:

Competitive landscape of a market explains the competition in the Direct Genetic Testing for Consumer Market taking into consideration price, revenue, sales, and market share by company, market concentration rate, competitive situations, trends, and market shares of top companies. Strategies incorporated by key players of the market such as investment strategies, marketing strategies, and product development plans are also further included in the report. The research integrates data regarding the producers product range, top product applications, and product specifications.

The major players in the Direct Genetic Testing for Consumer Market are:

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Direct Genetic Testing for Consumer Market.

Regional and Country-level Analysis

The market size information is provided by regions (countries) in the Direct Genetic Testing for Consumer Market report.

The key regions covered in the Direct Genetic Testing for Consumer Market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.

Tools Used for Analysis in This Report:

The Direct Genetic Testing for Consumer Market report has used analytical tools to include accurate research and evaluation data on key industry players and market coverage. Report Ocean experts have analyzed the growth of leading companies operating in the marketplace using analytics tools such as Porters five power analysis, SWOT analysis, feasibility study and ROI analysis.

Inquire or Share Your Questions If Any before Purchasing This Report:

Table of content

1 Direct Genetic Testing for Consumer Market Overview

1.1 Product Overview and Scope of Direct Genetic Testing for Consumer

1.2 Direct Genetic Testing for Consumer Segment by Type

1.2.1 Global Direct Genetic Testing for Consumer Production Growth Rate Comparison by Type 2020 VS 2026

1.2.2 Diagnostic Screening

1.2.3 Prenatal, Newborn Screening, and Pre-Implantation Diagnosis

1.2.4 Relationship Testing

1.3 Direct Genetic Testing for Consumer Segment by Application

1.3.1 Direct Genetic Testing for Consumer Consumption Comparison by Application: 2020 VS 2026

1.3.2 Online

1.3.3 Offline

1.4 Global Direct Genetic Testing for Consumer Market by Region

1.4.1 Global Direct Genetic Testing for Consumer Market Size Estimates and Forecasts by Region: 2020 VS 2026

1.4.2 North America Estimates and Forecasts (2015-2026)

1.4.3 Europe Estimates and Forecasts (2015-2026)

1.4.4 China Estimates and Forecasts (2015-2026)

1.4.5 Japan Estimates and Forecasts (2015-2026)

1.5 Global Direct Genetic Testing for Consumer Growth Prospects

1.5.1 Global Direct Genetic Testing for Consumer Revenue Estimates and Forecasts (2015-2026)

1.5.2 Global Direct Genetic Testing for Consumer Production Capacity Estimates and Forecasts (2015-2026)

1.5.3 Global Direct Genetic Testing for Consumer Production Estimates and Forecasts (2015-2026)

1.6 Direct Genetic Testing for Consumer Industry

1.7 Direct Genetic Testing for Consumer Market Trends

2 Market Competition by Manufacturers

2.1 Global Direct Genetic Testing for Consumer Production Capacity Market Share by Manufacturers (2015-2020)

2.2 Global Direct Genetic Testing for Consumer Revenue Share by Manufacturers (2015-2020)

2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.4 Global Direct Genetic Testing for Consumer Average Price by Manufacturers (2015-2020)

2.5 Manufacturers Direct Genetic Testing for Consumer Production Sites, Area Served, Product Types

2.6 Direct Genetic Testing for Consumer Market Competitive Situation and Trends

2.6.1 Direct Genetic Testing for Consumer Market Concentration Rate

2.6.2 Global Top 3 and Top 5 Players Market Share by Revenue

2.6.3 Mergers & Acquisitions, Expansion

3 Production and Capacity by Region

3.1 Global Production Capacity of Direct Genetic Testing for Consumer Market Share by Regions (2015-2020)

3.2 Global Direct Genetic Testing for Consumer Revenue Market Share by Regions (2015-2020)

3.3 Global Direct Genetic Testing for Consumer Production Capacity, Revenue, Price and Gross Margin (2015-2020)

3.4 North America Direct Genetic Testing for Consumer Production

3.4.1 North America Direct Genetic Testing for Consumer Production Growth Rate (2015-2020)

3.4.2 North America Direct Genetic Testing for Consumer Production Capacity, Revenue, Price and Gross Margin (2015-2020)

3.5 Europe Direct Genetic Testing for Consumer Production

3.5.1 Europe Direct Genetic Testing for Consumer Production Growth Rate (2015-2020)

3.5.2 Europe Direct Genetic Testing for Consumer Production Capacity, Revenue, Price and Gross Margin (2015-2020)

3.6 China Direct Genetic Testing for Consumer Production

3.6.1 China Direct Genetic Testing for Consumer Production Growth Rate (2015-2020)

3.6.2 China Direct Genetic Testing for Consumer Production Capacity, Revenue, Price and Gross Margin (2015-2020)

3.7 Japan Direct Genetic Testing for Consumer Production

3.7.1 Japan Direct Genetic Testing for Consumer Production Growth Rate (2015-2020)

3.7.2 Japan Direct Genetic Testing for Consumer Production Capacity, Revenue, Price and Gross Margin (2015-2020)

4 Global Direct Genetic Testing for Consumer Consumption by Regions

4.1 Global Direct Genetic Testing for Consumer Consumption by Regions

4.1.1 Global Direct Genetic Testing for Consumer Consumption by Region

4.1.2 Global Direct Genetic Testing for Consumer Consumption Market Share by Region

4.2 North America

4.2.1 North America Direct Genetic Testing for Consumer Consumption by Countries

4.2.2 U.S.

4.2.3 Canada

4.3 Europe

4.3.1 Europe Direct Genetic Testing for Consumer Consumption by Countries

4.3.2 Germany

4.3.3 France

4.3.4 U.K.

4.3.5 Italy

4.3.6 Russia

4.4 Asia Pacific

4.4.1 Asia Pacific Direct Genetic Testing for Consumer Consumption by Region

4.4.2 China

4.4.3 Japan

4.4.4 South Korea

4.4.5 Taiwan

4.4.6 Southeast Asia

4.4.7 India

4.4.8 Australia

4.5 Latin America

4.5.1 Latin America Direct Genetic Testing for Consumer Consumption by Countries

4.5.2 Mexico

4.5.3 Brazil

5 Direct Genetic Testing for Consumer Production, Revenue, Price Trend by Type

5.1 Global Direct Genetic Testing for Consumer Production Market Share by Type (2015-2020)

5.2 Global Direct Genetic Testing for Consumer Revenue Market Share by Type (2015-2020)

5.3 Global Direct Genetic Testing for Consumer Price by Type (2015-2020)

See the original post here:
Direct Genetic Testing for Consumer Market is expected to show impressive growth rate between 2020 to 2026 - LionLowdown

Hey, soldiers and spies think twice about that home genetic ancestry test – Roll Call

Companies such as 23andMe, AncestrybyDNA, Genebase andFull Genomes, for example, are among dozensthat provide consumer genetic testing to identify susceptibility to potential diseases as well as to establish genealogies. It's not clear which American companies, if any, have ties to Beijing or have sold data to China.

The request to study security risks posed by genetic testing companies signals a potentialnew area of concern that extends beyond the traditional espionage, cybersecurity and supply chain risks typically associated with Beijing's global reach.

Lawmakers appear to be concerned that U.S. officials working for intelligence agencies and the Pentagon, acting in their personal capacities, may be providing their genetic information to private testing companies that could end up in Chinese hands, giving Beijing highly sensitive information that it could combine with other information it already has on them to target officials for espionage or attack. The United States, for example, already has accused China of hacking the Office of Personnel Management sometime between 2013 and 2015 and taking away highly sensitive information on top U.S. officials.

The measure also would ask multiple intelligence agencies to step up vigilance on Chinese activities in the United States as well as inside the borders ofclose U.S. allies known as the Five Eyes, which include Australia, Canada, New Zealandand the United Kingdom.

Lawmakers want the CIA, the Office of the Director of National Intelligence and the Defense Intelligence Agency to submit a report on efforts by foreign adversaries to build and supply telecom and cybersecurity equipment forthe closest U.S. allies. The United States has put significant pressure on allies not to buy 5G equipment from China's Huawei, which Washington sees as a national security risk to U.S. communications networks.

More here:
Hey, soldiers and spies think twice about that home genetic ancestry test - Roll Call

Population Testing for Hereditary Breast and Ovarian Cancer Worthwhile? – Medscape

This transcript has been edited for clarity.

Today I'd like to ask: Is population testing for hereditary breast and ovarian cancer worthwhile?

In women with BRCA1 and BRCA2 mutations, lifetime risks for breast and ovarian cancer are high. Risk-reducing surgeries and other interventions can lower cancer risks in this population.

Investigators created a model to compare population testing in unselected women vs referring women with a high-risk family history for genetic counseling and possible testing. With this model, they found that population testing prevented more cancers than did family historybased testing.

Many carriers of hereditary breast and ovarian cancer genes are currently identified only after a diagnosis of malignancy, underscoring the potential benefits of population screening. However, it's not clear that this report has adequately assessed the downstream implications of population testing.

In my practice, if family history suggests that a patient is at elevated risk for breast or ovarian cancer, I refer her to a credentialed genetics counselor with special expertise in hereditary cancers. Once counseled, patients then decide whether or not to proceed with genetic testing, and the counselor works with the patient and her clinicians to determine appropriate responses to the results of genetic testing.

I was not able to identify that the investigators included pretest genetic counseling in their model of population screening. However, if genetic counseling is not performed, the task of interpreting test results falls on the patient and her clinicians.

Women may not be prepared to respond appropriately to the results of genetic testing without expert counseling. Clinicians may likewise feel inadequately prepared to help patients understand and act on test results. Some patients might undergo inappropriate risk-reducing surgeries and other interventions, while others who would benefit from such interventions might fail to pursue them.

The demand for genetics counselors currently has outstripped supply. I acknowledge that population screening for genes associated with breast and ovarian cancer could identify more mutation carriers. However, until we can ensure that women will have access to experts who can help them interpret results of genetic testing, I'll continue with my approach of referring patients with high-risk family histories to a genetic counselor.

Thank you for the honor of your time. I am Andrew Kaunitz.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Visit link:
Population Testing for Hereditary Breast and Ovarian Cancer Worthwhile? - Medscape

$2 million settlement reached in lawsuit against ob-gyn office in Norwich –

A $2 million settlement has been reached in a medical malpractice lawsuit filed by a Salem couple after their second daughter was born with cystic fibrosis. The mother said she accepted genetic testing at her obstetrician-gynecologists office, but the testing was never performed.

The mother, Elizabeth Trotter, who was pregnant with her first child in 2016 and a patient at OB-GYN Services in Norwich, said in a phone interview this week that she had wanted to be tested for everything because she did not know her medical history. She said she accepted genetic testing and thought the testing was performed.

She said she was told at 12 weeks that her blood work came back normal, so she assumed that meant everything was fine. She gave birth in January 2017 to a healthy baby girl, Paige.

When she was pregnant with her second daughter, Madelyn, now 2, she said she experienced a lot of complications, including preeclampsia and high blood pressure, and her daughter was born prematurely and spent over a month in the neonatal intensive care unit. Elizabeth, now 42,and her husband, Erik, now 47,found out during the newborn screen thatMadelyn was positive for cystic fibrosis.

The Trotters returned to OB GYN Services to ask how their daughter could have been born with this disease when the Cystic Fibrosis test performed on Beth in 2016 had been negative, according to The Reardon Law Firm, which represented the Trotters. The doctor consulted the records and determined that the test had never been ordered by the practice and had never been performed, despite being requested by Beth and acknowledged by the physician she spoke with.

Trotter said she got pregnant for the second time, without knowing that she was a carrier for cystic fibrosis and without being able to prepare.

Unfortunately, it took away our ability to make an educated choice for ourselves, and I truly feel that women should have the choice to figure out what is best for them and their family, Trotter said.

Herdoctor, David Kalla, declined to comment. A lawyer representing OB-GYN Services was out of the office until Monday and did not immediately respond to a request for comment.

Trotter said the settlement will help with expensive medical bills for her daughter's care. Cystic fibrosis "is a complex, chronic disease that primarily affects the lungs and digestive system," according to the Cystic Fibrosis Foundation.

The money that we did get from the settlement could be life-changing for her, she said. It could help her a lot with her care.

Trotter said she hopes the lawsuit brings more awareness to genetic testing and changes the standards of care for women. She added that sheis interested in potentially pursuing legislation that will empower womenand help themget genetic testing before they are pregnant.

Attorney Kelly Reardon, who settled the case for the maximum amount of insurance coverage available, said she believes what happened is that the practice had a relatively new electronic medical record software system and it was difficult to gain access to laboratory results through the software.

We think the fact that the test was never ordered was overlooked due to the software issue, she added.

She commended the Trotters for their courage and Dr. Kalla and the medical providers for taking the steps necessary to make sure the practice is more careful going forward about these types of errors. She said Dr. Kalla met with the family over Zoom to go over the changes.

I feel like it was an important case because it really allowed a family who went through a horrible situation to not only get financial compensation, which is important of course, but to also get some answers and have a conversation with the physician involved about the steps that his practice is taking to make sure that this type of scenario doesnt happen again, Reardon said.

The rest is here:
$2 million settlement reached in lawsuit against ob-gyn office in Norwich -

Genetic Testing Market is Rapid Growing with COVID-19 Impact Analysis, Top Key Companies Abbott Laboratories, Bio-Rad Laboratories Inc., Competitive…

Genetic Testing Marketis expected to register aCAGR of +11.50%and is projected to reachUSD 24,834.19 Million by 2028.The Global Genetic Testing Market is expected to register substantial growth in the near future due to rise in incidence of genetic disorders & cancer and growth in awareness and acceptance of personalized medicines. Genetic testing is also known as DNA testing. Genetic testing is the study of gene present in cells and tissues. This study is further applied in the field of biology and medicine to better understand genetic disorders such as cancer, sickle cell anemia, cystic fibrosis, Down syndrome, and others. The scope of the report discusses the use of gene tests for the development of personalized medicine, targeted cancer treatment, and other genetic diseases. In addition, advancements in genetic testing techniques and increasing application of genetic testing in oncology are expected to boost the market growth during the forecast period.Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. The Geographical Segmentation includes study of global regions such as North America, Latin America, Asia-Pacific, Africa, and Europe. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

Get Pdf Sample Copy of thisReport@

Profiling Key Players:

Highlighted key points of this market research report:

Get Upto 40% Discount Now @

Genetic Testing Key Market Segments:

By Product Type:

Predictive Testing

Carrier Testing

Prenatal & Newborn Testing

Diagnostic Testing

Pharmacogenomic Testing


By Technology Type:

Cytogenetic Testing/ Chromosome Analysis

Biochemical Testing

Molecular Testing

DNA Sequencing


By Application Type:

Chromosome Analysis

Genetic Disease Diagnosis

Cardiovascular Disease Diagnosis


Different top-level key players are also enlisted in order to obtain in-depth knowledge and informative data of companies. Some of the key players are also profiled in this research report, which includesGenetic TestingMarket. Different industry analysis tools such as SWOT and Porters five-technique are further used while analyzing the globalGenetic TestingMarket.

For More Inquiry Detailed TOC Of Research Report:

The report also draws attention to recent advancements in technologies and certain methodologies which further help to boost the outcome of the businesses. Furthermore, it also offers a comprehensive data of cost structure such as the cost of manpower, tools, technologies, and cost of raw material. The report is an expansive source of analytical information of different business verticals such as type, size, applications, and end-users. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Table of Content:

Chapter 1: Genetic Testing Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3: Genetic Testing Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Genetic Testing Market Effect Factors Analysis

Chapter 12: Global Genetic Testing Market Forecast to 2028

Finally,all aspects of the Genetic Testing Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us:AuthorKevinUS Address:51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225

Read more:
Genetic Testing Market is Rapid Growing with COVID-19 Impact Analysis, Top Key Companies Abbott Laboratories, Bio-Rad Laboratories Inc., Competitive...

Toddler who received heart transplant due to get baby brother – Newsday

For Christmas this year, toddler Ruby Cotter is getting a toy kitchen, a ball pit and a baby brother.

Ruby will become a big sister not having met many other children in her 18 months of life, according to her dad, Brian Cotter, 36. Shes been isolated to protect her weakened immune system that is compromised by medication she will need to take indefinitely to stop her body from rejecting the donated heart she got in transplant surgery last Christmastime.

Shes played with older cousins a few times, and one friend shes seen once or twice a month, Brian said, but "otherwise she doesnt interact with kids. Her brother will hopefully help her get used to that."

Ashley Cotter, 30 Brians wife and Rubys mom is pregnant with the couples second child, a boy they plan to name Everett Charles.

"We are thinking we might be welcoming him on Christmas," he said.

(The baby was due this past Wednesday, "so she could go into labor at any minute," Brian said. She will be induced if she doesnt give birth naturally by next Thursday, he said.)

Ruby has a rare, potentially fatal disorder called dilated cardiomyopathy, which restricts how blood is pumped to the body and vital organs. The disorder affects at least 1 in 100,000 children. She was born in June 2019 and hospitalized in September at NewYork-Presbyterian Hospital, in upper Manhattan, where she had two heart surgeries; the couple lived in the hospital for months to be with their daughter. She came home in January to Wading River, where the family lived at the time.

The pandemic has changed education on Long Island. Find out how.

By clicking Sign up, you agree to our privacy policy.

The couple, who have since moved to Shoreham, had discussed last year having more children, Ashley told Newsday last Christmastime, but wanted to do more genetic testing to figure out the odds a sibling of Ruby's could develop the same heart condition.

"I dont want to go through this again," Ashley Cotter said then. "I dont want to put another child through this again."

Brian said earlier this week that the couple did that genetic testing, and learned that the condition isnt in their genes.

"Well, to be honest, this pregnancy was not planned. We lived at the hospital for a long time without privacy and then the whole COVID lockdown happened," Brian said. "We did finish our genetic testing and found out that neither of us carry what caused Rubys condition. So far, our son looks very healthy."

The majority of cases of the disease are idiopathic meaning, arising without a known obvious cause rather than hereditary, according to a 2014 article in the journal Progress in Pediatric Cardiology.

Brian said the family is planning to have Rubys doctors examine their son soon after he is born.

Her parents hoped that she could begin to see people in the spring, but the coronavirus pandemic has meant that the family must stay virtually isolated due to her medication.

"She hasnt met too many other kids or babies, so it might be a shock for her," he said of her little-brother-to-be.

Still, Ruby is aware theres something going on in the family.

"She knows something is happening," Brian said, adding: "She does rub and kiss her moms belly."

Its the second successive Christmastime theres been good news for the Cotters. Just days before Christmas last year, Ruby got the transplant, in time for the holiday.

A GoFundMe account set up in 2019 to raise money for the family's nonmedical expenses food, bills, mortgage, and car payments had raised $114,055 as of this Christmas Eve.

With Rubys immune system medically compromised, the family has been careful about masking and social distance and other precautions. She was able to do outdoor activities when the weather was warmer and once went to a diner a month ago.

"Just her body language the whole time. Sitting in the booth, looking at all the lights. She was just smiling and eating pancakes and eggs. You can tell she appreciated it," he said.

But, Brian said as a second wave of the coronavirus hits the region, "now is not a good time to explore."

Last month, he said, Ruby started walking.

"She says a few words," Brian said. " No is her favorite."

Matthew Chayes, a Newsday reporter since 2007, covers New York City Hall.

View original post here:
Toddler who received heart transplant due to get baby brother - Newsday

Impact of COVID-19 on Pre-Pregnancy Genetic Testing Market 2027 Expected to reach Highest CAGR – The Courier

Worldwide Market Reports added Pre-Pregnancy Genetic Testing Market to its vast collection of research Databases. The report classifies the Global Pre-Pregnancy Genetic Testing Market in a precise manner to offer detailed insights into the aspects responsible for augmenting as well as restraining market growth.

A comprehensive analysis of the Global Pre-Pregnancy Genetic Testing Market is been done in this intelligence report. It includes the investigations done on past progress, ongoing market scenarios, and future prospects. Accurate data of the products, strategies, and market shares of leading companies in this particular market is mentioned. The report gives in-detailed information across Global regions, including Asia, North America, South America, Middle East, and Africa, Europe, with the sales and revenue data in each of the sub-segments.

Download Sample PDF of this Report @

Pre-Pregnancy Genetic Testing market competition by top manufacturers/players, with Pre-Pregnancy Genetic Testing sales volume, price, revenue (Million USD), and market share for each manufacturer/player; the top players including:Illumina (US), Natera (US), Ariosa Diagnostics (US), BGI Health (China), LifeCodexx (Germany)

Note: For a complete company list, please ask for a sample report.

We follow an iterative research methodology model to formulate the report that helps decision-makers take sound investment evaluation. Secondary research is carried out using internal and external sources to obtain qualitative and quantitative information of the market backed by the primary interview of KOLs and SMEs. This model negates any drastic deviation in the market estimation and is used to estimate the Pre-Pregnancy Genetic Testing Market size and forecasts until 2026.

The Pre-Pregnancy Genetic Testing Market report gives a 360-degree holistic view of the market and highlights the key developments, drivers, restraints, and future trends with impact analysis of these trends on the market for short-term, mid-term, and long-term during the forecast period. In addition, Along with an industrial chain, market statistics in terms of revenue, sales, price, capacity, regional market analysis, segment-wise data, and market forecast information are offered in the full study, etc.

Industrial Impact of Covid-19 on Pre-Pregnancy Genetic Testing Industry:

The outbreak of the pandemicCOVID-19changed the market scenario on the global platform. Many of the regions are facing the biggest economic crisis owing to the lockdowns that were implemented due to the outspread of the coronavirus infection. As the only solution that has been found to contracting this disease is social distancing many countries have implemented strong regulations in regards to people gatherings. Owing to this many of the businesses are working with only 30% of its employees thus not able to bring the maximum production.

Thiscan affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Do You Have Any Query Or Specific Requirement? Drop Your Query Here @

Pre-Pregnancy Genetic Testing Market Report is Segmented as Following-

In the end, the Pre-Pregnancy Genetic Testing report offers a short outline of the dealers, distributors, suppliers. Along with the Pre-Pregnancy Genetic Testingsales channel, analysis findings, conclusions, and results. Finally, provide info regarding new entrants within the Pre-Pregnancy Genetic Testing market. The study suggests a brand new proposition to spice up the Pre-Pregnancy Genetic Testing market price and nurture businesses. Correspondingly explains the current global Pre-Pregnancy Genetic Testing market and the coming development of the business. The Pre-Pregnancy Genetic Testing Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure, and all these together will help leading players understand the scope of the Market, what characteristics it offers, and how it will fulfill customers requirements. The study also covers market status, share, future patterns, development rate, deals, SWOT analysis, channels, merchants, and improvement gets ready for the anticipated year between 2020-2027.

Download PDF of This Report @

About Worldwide Market Reports:

The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Reports well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Organization:Worldwide Market Reports

Phone:+1 415 871 0703

Visit Our Blog:BJ

Read more from the original source:
Impact of COVID-19 on Pre-Pregnancy Genetic Testing Market 2027 Expected to reach Highest CAGR - The Courier

DTC Genetic Testing Market Size By Type, By Application, By Geography, By Top Companies And Forecast To 2027 – LionLowdown

New Jersey, United States: The most recently added report on DTC Genetic Testing Market Insights, Forecast 2020 to 2027, Market Analysis report encourages clients to make strategic business decisions and understand the industry competitive advantage and key players strategies. of the market. The most recently added report on the DTC Genetic Testing Market has qualified and verifiable market insights conducted in the current scenario.

The research report of the DTC Genetic Testing market offers detailed information and overviews of the market for the forecast period 2020 to 2027. The major competitors in the DTC Genetic Testing market and their competitive landscapes are analyzed as they are market leaders and are concerned in the front. The report also takes into account the critical points of the market and offers important solutions for the growth of the market. In addition, the report also examines the raw materials supply chain channels, sales channels, and production flows of the major market players.

DTC Genetic Testing Market: Competitive Landscape

Competitive Analysis is one of the best sections of the report, comparing the progress of leading companies using key metrics like market share, new developments, global reach, local competition, pricing, and production. From the nature of the competition to future changes in the vendor landscape, the report offers an in-depth competitive analysis in the DTC Genetic Testing market.

Major Key Players Operating in the Market:

DTC Genetic Testing Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

DTC Genetic Testing Market Segment by Type:

DTC Genetic Testing Market Segment by Application:

DTC Genetic Testing Market Regional overview:

In the report, experts analyze and forecast the DTC Genetic Testing market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Major Key Points Covered in DTC Genetic Testing Market:

Key questions in the report:

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080


Visit link:
DTC Genetic Testing Market Size By Type, By Application, By Geography, By Top Companies And Forecast To 2027 - LionLowdown